BridgeMD
New treatment option for Psoriasis (PsO)
Official title A Phase 2 Study of HB0017 in Psoriasis Patients
ClinicalTrials.gov ID: NCT06592274
What this study is testing
What is HB0017?
HB0017 is an investigational medicine, given as an injectable medicine, being studied as a potential treatment for psoriasis (pso).
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study is a randomized, double-blind phase 2 clinical trial aimed at exploring the efficacy, safety, and immunogenicity of HB0017 injection with different dosing regimens in the treatment of moderate to severe plaque psoriasis in subjects
- Phase 2: a mid-size study of how well it works
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 75
You may be able to join if
- Male or female people aged 18-75 years (inclusive)
- Chronic plaque psoriasis (PSO) for at least 6 months prior to the randomization.
- Psoriasis Area Severity Index (PASI) \>=12 and body surface area (BSA) affected by PSO \>=10% and Static Physician Global Assessment (sPGA) score...
- people who are suitable for systemic treatment or phototherapy for psoriasis as judged by the investigator
- people who are able to use effective contraception from the screening period to 6 months after the last dose
You likely can't join if
- Forms of psoriasis other than chronic plaque-type (e.g., pustular, erythrodermic and/or guttate psoriasis) at screening or baseline Drug-induced...
- Ongoing use of prohibited treatments
- Any active infection (other than common cold) within 14 days
- Serious infection defined as requiring hospitalization or iv anti-infective(s) within 1 month prior to randomization
- Have previously received any drug that directly targets IL-17 or IL-17 receptor
- Have concurrent or recent use of any biologic agent within the following washout periods: etanercept \<28 days; infliximab and adalimumab \<60 days...
See the full eligibility criteria
- Male or female people aged 18-75 years (inclusive)
- Chronic plaque psoriasis (PSO) for at least 6 months prior to the randomization.
- Psoriasis Area Severity Index (PASI) \>=12 and body surface area (BSA) affected by PSO \>=10% and Static Physician Global Assessment (sPGA) score \>=3.
- people who are suitable for systemic treatment or phototherapy for psoriasis as judged by the investigator
- people who are able to use effective contraception from the screening period to 6 months after the last dose
- Forms of psoriasis other than chronic plaque-type (e.g., pustular, erythrodermic and/or guttate psoriasis) at screening or baseline Drug-induced psoriasis
- Ongoing use of prohibited treatments
- Any active infection (other than common cold) within 14 days
- Serious infection defined as requiring hospitalization or iv anti-infective(s) within 1 month prior to randomization
- Have previously received any drug that directly targets IL-17 or IL-17 receptor
- Have concurrent or recent use of any biologic agent within the following washout periods: etanercept \<28 days; infliximab and adalimumab \<60 days; golimumab \< 90 days; anti-IL-12/anti-IL-23 or anti-IL-23p19 antibody...
- A history of inflammatory bowel disease or other serious autoimmune disease
- Previously diagnosed with serious mental illness such as anxiety, depression or suicidal tendency
The study team makes the final eligibility decision.
Where it's taking place
- Bengbu, Anhui, China
- Guangzhou, Guangdong, China
- Changsha, Hunan, China
- Wuxi, Jiangsu, China
- Zhenjiang, Jiangsu, China
- Changchun, Jilin, China
- Jinan, Shandong, China
- Jining, Shandong, China
- Xingtai, Shandong, China
- Taiyuan, Shanxi, China
- Chengdu, Sichuan, China
- Chongqing, Sichuan, China
- Hangzhou, Zhejiang, China
- Jiaxing, Zhejiang, China
- Wenzhou, Zhejiang, China
- Guangzhou, China
- Ningbo, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 75 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Bengbu, Anhui, China; Guangzhou, Guangdong, China; Changsha, Hunan, China; Wuxi, Jiangsu, China; Zhenjiang, Jiangsu, China; Changchun, Jilin, China and 11 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.